The Minimal-Basis Run Gave T4-Lysozyme the Wrong Binding Sign: What Cleveland Clinic, RIKEN and IBM Changed to Correct It
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 9 September 2026 Cleveland Clinic announced that a team from Cleveland Clinic, the RIKEN Center for Computational Science and IBM had reached the finals of the 2026 ACM Gordon Bell Prize, for quantum-classical electronic-structure calculations on protein-ligand complexes of 11,608 and 12,635 atoms. Four days earlier the preprint behind that entry gained a second version, and buried in it is a result that deserves more attention than the atom count.
When the team computed the binding energy of a well-studied protein-ligand pair in a minimal basis set, the answer came out too positive, which is to say it pointed the wrong way for a ligand known to bind. Recomputing it with richer orbitals in the binding region and a tighter bath threshold together corrects the sign of the binding energy, at about ten times more in total node-hours. The revision also reports a first end-to-end wall-clock time, 62.4 hours from fragment generation to energy reconstruction, for a bound-complex ground-state run.
Hefei Mandi's Magnetocardiograph, 4 and 5 August 2026: Two Unresolved Deployment Descriptions in Chinanews and Xinhua
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 4 August 2026 a state press tour called Vibrant China Field Study visited the Institute of Health and Medicine at the Hefei Comprehensive National Science Center and watched a magnetocardiograph acquire signal in the laboratory of Hefei Mandi Medical Technology. Two reports came out of that visit on consecutive days, both from official Chinese outlets, both describing the same machine, and they describe its stage of deployment in different words that no public source resolves.
The company builds a magnetocardiograph around a superconducting quantum interference device, the detector class that reads magnetic fields at the femtotesla scale, and a 2022 industry profile says it obtained an NMPA registration in 2019. The 4 August report describes the machine as working with ten key hospitals in scientific research collaboration and entering a pre-mass-production stage. The 5 August report describes it as installed and in use at more than ten key hospitals in deployed application, with the company's production lines running at full load. A hospital deciding whether to buy one needs to know which of those two sentences is the current state of the product.
A 280-Nanometre Diamond Reached a 682 Microkelvin Resolution Floor: Cambridge, Warwick and Cardiff, 4 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 4 September 2026 a group drawn from the Cavendish Laboratory at the University of Cambridge, the University of Warwick and Cardiff University posted a preprint on nanoscale thermometry with a free-standing diamond particle. Jack W. Hart, Soham Pal, Julien R. E. Roth, Katie Ninham, Abbie H. Aleksandrova, Xander Peetroons, Soumen Mandal, Oliver A. Williams, Gavin W. Morley, Mete Atature and Helena S. Knowles report that the platform as a whole reaches roughly an order of magnitude better sensitivity than previously published nanodiamond figures.
Three numbers carry the result, and each needs its qualifier. The paper reports an extrapolated resolution floor of 682 microkelvin, a figure derived from the fitting error of the functional form rather than from a single demonstrated reading; the average error on a temperature measurement that took 83 seconds to acquire was 11.9 millikelvin. The sensor is a 280-nanometre nanodiamond ball-milled from isotopically purified carbon-12, small enough in principle to sit inside a cell and holding two nitrogen-vacancy centers rather than one. And the same paper measures the heat its own readout laser pours into the sample, finding 337 millikelvin of heating for every milliwatt of incident optical power, with an observed maximum rise of 224 millikelvin at 0.63 milliwatts, which is some 330 times the extrapolated resolution floor.
Japanese Patent 7,908,389, Registered 10 August 2026: What Toshiba and AOI Biosciences Claim for Allosteric Site Prediction, and What Quantum-Inspired SQBM+ Actually Runs On
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 3 September 2026 Toshiba Corporation and AOI Biosciences announced that a patent the two companies had filed together was registered in Japan on 10 August 2026. It covers an allosteric pathway prediction device: software that reads a protein's three-dimensional structure and predicts the internal routes leading to pockets that sit away from the site where the protein does its work.
Three parts of that announcement carry different weights. Japanese Patent 7,908,389 is a legal instrument whose protection runs to its granted claims in Japan, which is a separate question from whether the method finds sites nobody had found before. The supporting evidence offered in the release is one figure, accuracy of 80 percent or higher on already-known sites, reported without a definition of accuracy, a benchmark set or a paper behind it. And the optimization engine at the center of the work, Toshiba's SQBM+, is described as quantum-inspired, a term that here means the solver runs on ordinary classical computers and uses no qubits.
A Sleep App's Cough Data Showed a One-Week Lead on Flu and COVID-19 PCR Positivity in Retrospective Analysis: What UKHSA and Sleep Cycle Published on 3 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
On 3 September 2026 the UK Health Security Agency published the results of a joint study with Sleep Cycle, a Swedish sleep-technology company, reporting that increases in coughing at night were often seen about a week before increases in influenza and COVID-19 activity in England. The underlying data came from a consumer smartphone app that listens while people sleep, and the preprint states that no raw audio is transmitted to Sleep Cycle's servers.
The claim worth reading closely is the smaller one. Across three years of weekly data the nocturnal cough measures moved almost in step with NHS 111 triage calls for acute respiratory infection, and only secondarily did they show a one-week lead in retrospective analysis over PCR positivity for influenza and COVID-19. The agency and the authors are careful about what that supports. The study looked backward at three respiratory seasons that have already happened, so what it establishes is a relationship in recorded data, and the authors write that operational usefulness would need a prospective evaluation against forecasting benchmarks in a live setting.
Quantum Foundry Copenhagen Plans a 5,300-Square-Meter Quantum Chip Factory for 2027: What the Novo Nordisk Foundation Announced on 4 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A health foundation announcing a chip plant is unusual enough to state plainly. On 4 September 2026 the Novo Nordisk Foundation and Quantum Foundry Copenhagen, the company the foundation started in 2023 and owns, said they will build a 5,300-square-meter quantum chip fabrication facility in Copenhagen, with an opening expected in 2027. The plant is to combine nanofabrication of quantum materials, characterization, testing, chip assembly and packaging, and it is to sell wafer fabrication to quantum technology vendors elsewhere in the world on commercial terms.
The foundation's own Danish announcement puts faster development of new medicine among the reasons for spending the money. Its total commitment to quantum technology now exceeds DKK 2.9 billion, about EUR 390 million, and the factory is the manufacturing end of it. Two days earlier the engineering firm Ramboll handed over the Copenhagen building that will house Magne, the machine the foundation co-owns through QuNorth. Both projects run toward the same declared destination, a fault-tolerant quantum computer in Denmark before 2034, and a clinician reading the announcement is entitled to ask what any of it does for a patient in the meantime.
OpenEvidence Released Osler, Sackett and Snow Free on 3 September 2026 and Gated Darwin on Dual-Use Grounds: What a Perfect Score on 660 MedQA Questions Shows
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
OpenEvidence assigns its quickest model about five seconds per answer and its deeper modes thirty seconds and five minutes, and on 3 September 2026 the Miami company, whose search tool is used by a majority of US physicians on its own account, split its product along that line. Three models that differ in how long they think were released free to every verified clinician, and a fourth, described as its most capable, is one a researcher must apply to use. The company's stated reason for the fourth is that a model able to reason at the frontier of virology, immunology and human genetics could also, in the wrong hands, accelerate work the world tightly governs.
The release names Darwin as the withheld model and reports that it answered a physician-cleaned set of 660 MedQA questions without a single error, along with 72.8 percent on MedXpertQA, 82.7 percent on HealthBench Professional and 87.2 percent on the NOHARM harm benchmark. The dual-use rationale is stated in one sentence and the access rule in another, and the company has published its annotations and its model's full outputs for the four benchmarks. This Monitor reads what the 660 questions and the other three scores can support, how the company chose the comparators and the judge, and what the access decision looks like beside the framework the founder of this site published for exactly this kind of choice.
NEO, the First Approved Implantable BCI, and the NSCEB's Gap List of 2 September 2026: What China Has in Place, What the US Lacks, and a 1,951-Character Mandarin Claim With No Located Paper
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A person with a cervical spinal cord injury can imagine closing a hand for years without the hand moving. The brain still issues the command; the spinal cord no longer carries it. A brain-computer interface reads the command above the break and sends it to a machine that does the closing. Regulatory approval, manufacturing capacity and reimbursement all decide whether such a device reaches routine care, and this week the two largest medical markets showed how differently they handle the three.
On 13 March 2026 China's National Medical Products Administration granted market approval to NEO, an implantable brain-computer interface for hand motor function developed by Neuracle, known in Chinese as Boruikang, with Tsinghua University. On 2 September 2026 the US National Security Commission on Emerging Biotechnology published an analysis that called it the world's first commercial approval of an implanted BCI and listed four missing US mechanisms. The same week brought a Chinese magazine profile claiming 1,951 Chinese characters decoded from an implant, and a Taiwanese report on a US company that wants to read the brain through the nose. This Monitor reads the cluster for what each item can support.
IIT Roorkee, 2 September 2026: A Fluorescent-Protein Spin Qubit Six to Eight Orders Short of Neural Nitric Oxide
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
An individual nitric oxide molecule diffuses about two nanometers in roughly 0.2 nanoseconds, which makes the signal close to its point of production exceptionally transient. The methods available today each miss that measurement in a different way: a microelectrode cannot be placed with nanometer precision, a small-molecule indicator disturbs the redox chemistry it is there to report, and neither reads the radical's own magnetism. On 2 September 2026 five researchers at three Indian institutes published the calculation that says how far one new class of protein sensor sits from doing that job.
The preprint, posted to arXiv as 2609.02792 by Parul Raghuvanshi, Sagnik Ganguly, Sharika E, Mohana Priya T. and Vishvendra S. Poonia of IIT Roorkee, IIEST Shibpur and IIT (ISM) Dhanbad, works out the detection limit for spin relaxometry with the fluorescent-protein spin qubit. Their verdict on the sensor as it exists today is that it misses physiological concentrations of nitric oxide by six to eight orders of magnitude. The bottleneck they identify is the qubit's own relaxation time, which is set by the vibrations of the protein that houses it.
What Feder and colleagues published in Nature on 20 August 2025: a spin-1 qubit inside enhanced yellow fluorescent protein
The object this calculation is about was demonstrated last year. Jacob Feder, Benjamin Soloway and their co-authors reported in Nature 645, 73 (2025) that enhanced yellow fluorescent protein hosts an optically addressable spin-1 qubit in the metastable triplet state of its chromophore. The qubit is initialized by 488 nanometer light through spin-selective intersystem crossing, driven by microwaves, and read out through optically activated delayed fluorescence, in which a 912 nanometer pulse lifts the triplet through a higher triplet state back into the singlet manifold. The delayed light that comes back is separated in time from prompt autofluorescence, so the emission carries the spin state.
Its Hamiltonian is a spin-1 with zero-field splitting, measured at D of 2.356 gigahertz and E of 0.458 gigahertz, which puts three zero-field magnetic resonance lines at roughly 0.92, 1.90 and 2.81 gigahertz. The property that matters for medicine is not spectroscopic. Because the sensor is a protein, a cell can be instructed to build it, and it can be fused to a chosen partner protein. That places the sensor spin within the three-nanometer barrel of an enzyme that makes the very radical one wants to measure. This Monitor read the wider case for cells that grow their own quantum sensors on 26 August 2026; the paper now under discussion is the first hard test of whether the idea survives contact with numbers.
BC World Pharm Announced on 1 September 2026 That It Was Selected With Qunova Computing to Target Pan-Beta-Lactamase and Penicillin-Binding Proteins
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
An infectious disease physician facing a resistant Gram-negative infection chooses among a small number of remaining drugs. The reason the number is small is chemical. Bacteria carrying beta-lactamase enzymes cut the beta-lactam ring before the antibiotic reaches the protein it was meant to block. One clinical strategy has been to pair the antibiotic with an inhibitor that protects it, and that strategy keeps running out because the approved inhibitors do not cover every enzyme.
On 1 September 2026 BC World Pharm announced that it had been selected as lead research institution for a Korean government project intending to find compounds that hit pan-beta-lactamase and penicillin-binding proteins at the same time, with Qunova Computing, a quantum computer based computational chemistry company, as co-research institution. The cited announcements state no budget or project term, and no ministry award record was reachable during this reading.
The two targets do different jobs. Penicillin-binding proteins build the bacterial cell wall and are what every beta-lactam antibiotic is aimed at. Beta-lactamases are the defense the bacterium evolved against exactly that, and they fall into four Ambler classes, three of which cut with a serine residue while class B uses zinc. Hamrick and colleagues place clavulanic acid and tazobactam mainly against class A, describe avibactam as reaching classes A, C and D, and report that no inhibitor approved as of 2020 covered both the clinically important serine enzymes and the metallo enzymes. Their own subject, taniborbactam, reached all four classes with one documented exception, IMP-1. Those limits sit alongside the World Health Organization's priority pathogens list of May 2024, which puts carbapenem-resistant Enterobacterales in its critical group.
Qunova Computing was founded in 2021 by a KAIST professor and is based in Daejeon; the company reports that its HI-VQE algorithm has run quantum chemistry problems at qubit counts up to 68 and sits in IBM's Qiskit functions catalog. The announcement describes AI and quantum mechanics based multi-target design without identifying a method, a backend or a hardware result, and quantum mechanics based design is also standard vocabulary for classical quantum chemistry, which limits what can be inferred about quantum-hardware involvement. This is the second reported Korean selection in a week pairing a pharmaceutical company with a computational drug-design company, after D&D Pharmatech and Quantum Intelligence on 28 August, and the two run under different ministry instruments.
OpenAI Connected ChatGPT to Epic Charts on 1 September 2026, With Read-Only Access
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A clinician preparing for an afternoon appointment spends the first minutes of it reading: the last visit note, the newest labs, the medication list, whatever the specialist sent over. On 1 September 2026 OpenAI said that reading can be handed to ChatGPT, working from the patient's own Epic record.
Two capabilities ship together. Health organizations can connect their Epic electronic health record environments to ChatGPT for Healthcare, and a separate Healthcare Public Data plugin wires the same workspace to nine official public datasets, among them ClinicalTrials.gov, CMS Coverage, RxNorm, DailyMed and PubMed. Access to the chart is read-only. The model writes nothing back into the record.
Two things carry this deployment to the bedside, and a regulatory clearance is neither of them. The first is a business associate agreement, the contract HIPAA requires before an outside vendor may handle protected health information. The second is OpenAI's own physician evaluation, which reports 4,363 ratings across 27 clinical use cases, with 99.1 percent of responses graded safe.
Those figures come from evaluation results OpenAI published itself, and the company says so. The denominator is ratings, and the announcement does not say whether one response could receive several of them, so 99.1 percent of 4,363 leaves approximately 39 non-safe ratings rather than a countable set of unsafe answers. No definition of the safety rating is published: the announcement does not say what the scale was, what those 39 ratings concerned, how severity was graded, or whether reviewers were blinded to the source of the answer.
Where the product lands against FDA's four criteria for clinical decision support software, the fourth of which asks that a clinician can independently review the basis for a recommendation, is an open question that read-only access does not settle on its own, and the announcement reports no determination. The decision support interventions criterion at 45 CFR 170.315(b)(11) reaches interventions a developer supplies with its own health IT module, which leaves the scope question for a hospital to settle with its vendors.
QC Ware and IonQ Mapped Four Orbitals of a Cytochrome P450nor Active Site Onto Eight Qubits of IonQ Forte on 1 September 2026
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
How tightly a candidate binds its target is one important factor in whether a drug works, and metal centers are among the difficult cases to calculate: an iron atom sitting in the middle of an enzyme. On 1 September 2026 QC Ware and IonQ said they had measured a four-orbital slice of one such site on a quantum computer and landed close to the classical answer. QC Ware's Promethium platform did the classical preparation, IonQ's Forte trapped-ion processor took the quantum measurement through Amazon Braket, and the target was the heme active site of cytochrome P450nor. The workflow calculated an electrostatic interaction energy within 0.5 kcal/mol of classical benchmarks, roughly four percent, inside the one kcal/mol threshold conventionally called chemical accuracy.
The IonQ half of a workflow already run on IBM hardware
This is a follow-up. On 7 August 2026 this Monitor read the same QC Ware Promethium workflow running a nitric oxide reductase calculation on IBM's 156-qubit Heron processor. The platform, the enzyme family and the hybrid division of labor are unchanged; the processor underneath is what is new, which makes hardware portability the company's actual claim. Portability is not comparability: the August disclosure carried no numerical result that today's figure could be set against. Today's release adds four disclosures the August account did not carry: the 115-atom active-site model, its more than 1,000 molecular orbitals, the reduction to a four-orbital active space mapped onto eight qubits, and the 0.5 kcal/mol comparison itself.
What the quantum machine actually did
The quantum step ran on eight qubits of a 36-qubit machine, measuring a four-orbital slice carved out of a model containing more than a thousand molecular orbitals. Promethium built the model, identified the strongly correlated region, reduced it automatically to that active space, and computed the final interaction energies classically after Forte measured the qubits in a single basis. Everything before and after the quantum slice happened on classical hardware.
Which enzyme, and why the framing needs care
P450nor sits in the cytochrome P450 superfamily whose monooxygenase members carry out most human drug metabolism, and the release says exactly that. P450nor itself is something else: a fungal CYP55 nitric oxide reductase, characterized in Fusarium oxysporum among other fungi, reducing nitric oxide to nitrous oxide and taking its electrons straight from reduced nicotinamide adenine dinucleotide, NADH. The release names no organism and no accession. It is a well-characterized computational test case, which is a good reason to choose it for a hardware demonstration and a poor reason to describe the run as modeling human drug metabolism.
What the result can and cannot establish
The comparison target was a classical benchmark, so the classical answer existed first, and the companies report agreement for this known case. The announcement names no preprint, reports no shot count, gives no uncertainty on the 0.5 kcal/mol figure and does not identify which classical method produced the benchmark.
Tecnun's Synthetic Myelodysplastic-Syndrome Patients Were Seven-Bit Samples From IBM's ibm_basquecountry
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
The SintraREV trial randomized 61 patients. It ran from 15 February 2010 to 21 February 2018 across 22 university hospitals in Spain, France and Germany, and eight years of enrollment for 61 people is what a phase 3 study costs in a rare blood cancer. A preprint posted on 28 August 2026 takes the data from that trial and asks whether a quantum computer can generate synthetic patients good enough to stand alongside them.
Olatz Sanz Larrarte and nine co-authors published "A quantum generative model for in silico clinical trials using scarce training datasets" on arXiv on 28 August 2026, accepted for the proceedings of the CIBB 2026 conference. The author list crosses two worlds. Sanz Larrarte, Reza Dastbasteh, Pedro Crespo Bofill and Josu Etxezarreta Martinez work in the Department of Basic Sciences at Tecnun, the University of Navarra engineering school in San Sebastián. María Díez-Campelo of the hematology department at Hospital Universitario de Salamanca led SintraREV itself. Felipe Prosper and Ana Alfonso-Piérola practice at the Clínica Universidad de Navarra, Mikel Hernaez and Roberto Sanchez-Navarro sit at CIMA and DATAI in Pamplona, and Sara Capponi is at IBM Research in San Jose. The circuits ran on ibm_basquecountry, the 156-qubit Heron r2 processor in Donostia-San Sebastián.
Practical takeaway. The synthetic patients this pipeline produces are seven-bit strings. Sex, age, hemoglobin, platelets, neutrophils, treatment assignment and survival are each reduced to a single yes-or-no value, and the quantum processor samples from a distribution over those 128 possible patients. The fitting step that classical generative models spend hundreds of training epochs on happens on a classical computer before the quantum machine is touched.
Florida Atlantic's 90.26% Quantum Heart-Disease Result Came From a Simulator: the AI Paper of 21 May 2026 and the FAU Release of 27 August
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
Florida Atlantic University announced on 27 August 2026 that its engineers had built a quantum machine learning framework for heart disease prediction reaching more than 90 percent accuracy. The figure is precise and it is checkable. It is 90.26 percent, produced by a quantum support vector machine with angle encoding, averaged across five folds of a clinical file holding 918 patients.
The work behind that announcement appeared three months earlier. Muhammad Minoar Hossain, Md. Hasibul Hassan Himal and Arslan Munir published "A Comparative Study of Quantum Feature Maps and Quantum Classifiers for Heart Disease Prediction" in the MDPI journal AI on 21 May 2026, as article 180 of volume 7, under a Creative Commons license that lets anyone read the whole methods section. Section 2.6.2 of that paper states that every quantum experiment ran in a simulation-based environment rather than on a physical quantum processing unit. The university announcement does not carry that sentence, and neither does the coverage that followed it.
That difference decides what the study is evidence for. Simulated qubits establish whether an algorithm has promise in principle; a run on a physical processor establishes whether the machines that exist can deliver it, once noise, limited connectivity and readout error have had their say. Everything else in the paper holds up well under checking. Several of its numbers are more informative than the ones the announcement chose to lead with, and one of them disagrees with the paper's own abstract. The study is a careful piece of comparative work whose careful parts were the first thing lost in transmission.
Stony Brook Aims Its Quantum Network at University Hospital Patient Data: What the 21 August Link to Brookhaven Actually Carried
Quentir Medicine Monitor
Evidence-based insights for quantum medicine.
A 375-square-foot galvanized steel chamber now sits on the roof of Stony Brook University's Health Sciences Center, fourteen floors above the medical campus and reached by two final flights of stairs. Its builders call it the Quantum Watchtower, and they say the instruments inside will one day protect Stony Brook University Hospital patient data against cyberattack by teleporting quantum information.
That sentence was published on 28 August 2026 by Jess Stallone in Stony Brook Matters, the university's news site for alumni. One week earlier, on 21 August, Stony Brook and the Department of Energy's Brookhaven National Laboratory announced the demonstration behind it: a working free-space optical link carrying quantum information across 13 miles of open Long Island air. For a hospital reader the useful exercise is to hold the two statements next to each other, because they describe different stages of the same project.
What crossed the 13 miles between Stony Brook and Upton on 21 August 2026
The Watchtower is one end of a pair. The other is the Quantum Lighthouse, a nearly identical steel structure built by Brookhaven Lab at Upton, New York, 13 miles east, positioned for a clear line of sight back to campus. At the "First Light" event on 21 August, researchers generated quantum states of light at the Stony Brook rooftop and sent them across the open air to the Lighthouse. The university describes what was transmitted as "quantum states of light, each containing just a few individual photons," which is a weak coherent source rather than a true single-photon emitter. That daytime run demonstrated that the optical path could be aimed and held steady.
The entanglement work happened separately, at night, when the sky's background light drops far enough for faint signals to be picked out. Entangled photon pairs were generated in a Stony Brook physics laboratory, carried by fiber to the Watchtower, launched across the 13 miles, and measured at the Lighthouse. Justine Haupt, the Brookhaven engineer leading the link, came to it from astronomical instrumentation. "It's exciting to take capabilities we've spent years refining for astronomy and adapt them for a completely different scientific problem," she said.
Nanodiamond Charge Drift Reads Macrophage Inflammation: Chicago and Iowa in Advanced Materials, 4 February 2026
Nanodiamond quantum sensors have been read as thermometers inside living cells for more than a decade. One of them, a 70-nanometer crystal sitting inside a mouse macrophage, drifted downward by 0.27 megahertz over 200 seconds of measurement, which on the usual arithmetic means the cell warmed by 3.62 degrees Celsius. A team at the University of Chicago and the University of Iowa has now put a different quantity behind that same number.
Their paper, Probing cellular activity via charge-sensitive quantum nanoprobes, appeared in Advanced Materials on 4 February 2026, with Uri Zvi as first author and Denis R. Candido at Iowa, Aaron Esser-Kahn and Peter C. Maurer at Chicago as corresponding authors. It was received on 15 March 2025 and accepted on 15 January 2026. The University of Iowa publicized it on 26 August 2026, six months after the article went online, which is why it reaches this Monitor now.
What the zero-field splitting actually tracks, and the dipole term that was being dropped
The sensor is a nitrogen-vacancy center, an atomic defect in diamond whose spin can be initialized with green light, driven with microwaves and read out optically. Each 70-nanometer crystal used here carries roughly 100 of them. The measured quantity is the zero-field splitting, the frequency gap between the spin's ground sublevels, which sits near 2.87 gigahertz and moves by about 74 kilohertz for every kelvin. That temperature coefficient is what turned these particles into intracellular thermometers in the first place.
A*STAR Put an 18-Variable Drug-Docking Problem on Six Qubits of IBM's ibm_kingston
Six qubits for an eighteen-variable docking problem
On August 20, 2026 six researchers at institutes of Singapore's Agency for Science, Technology and Research, the National University of Singapore and Nanyang Technological University posted a preprint describing a hybrid quantum-classical method for molecular docking, and executed its circuits on IBM's ibm_kingston processor. Molecular docking is the everyday question of early drug research: given a candidate molecule and a target protein, how does the molecule seat itself in the pocket, and how well. The team recast that question as a graph problem, where each plausible contact between ligand and protein is a weighted vertex and the winning binding pose is the heaviest set of contacts that can all coexist.
An encoding that carries three variables on one qubit
The contribution is an encoding the authors call full-basis encoding, which uses all three orthogonal directions of a qubit's Bloch sphere to carry information instead of one. That put an 18-variable problem on six qubits for the streptavidin-biotin complex 1STP, and a 14-variable problem on five qubits for trypsin with benzamidine, entry 9AW2. The paper also proves that a global minimizer of its objective can always be chosen to be a pure product state, so the optimum requires no entanglement between qubits and the circuits can stay shallow enough for current hardware. What changed for a reader tracking this field is the qubit cost of a docking problem, since the number of good qubits a problem consumes is the binding constraint on machines available today.
What the hardware runs did and did not settle
On both instances the runs on ibm_kingston recovered the same vertex selections as the classical simulation and matched the known clique structure under realistic gate noise and readout error. The authors state plainly that this is evidence of feasibility and that quantum advantage is not demonstrated, since both test problems were deliberately kept small enough for classical verification. Streptavidin with biotin and benzamidine in the trypsin pocket are textbook complexes, though their records differ in age: entry 1STP has been public since 1992, while entry 9AW2 is a 2025 redetermination of a complex first characterized in the mid-1970s. Either way the correct answer was known before the circuits ran, which is what made the check against ground truth possible and also what limits the claim. The open question the authors name themselves is whether the compression ratio survives realistic docking graphs with hundreds of vertices, alongside better ansatz design and hardware-aware circuit compilation.
Cells That Grow Their Own Quantum Sensors
A quantum sensor the cell builds for itself
On August 25, 2026 the United States National Science Foundation renewed the University of Chicago-led Quantum Leap Challenge Institute for Quantum Sensing for Biophysics and Bioengineering with a 37.5 million dollar, five-year cooperative agreement running from September 1, 2026 to August 31, 2031, with Chicago State University, the University of Illinois Chicago and Harvard University as partners. The scientific bet underneath the renewal is that a genetically encoded quantum sensor can be written into a cell's DNA and manufactured by the cell itself, rather than fabricated externally and delivered into the cell from outside.
Why genetic encoding matters here
Nanoscale quantum sensing in living systems has until now meant the nitrogen-vacancy center, an atomic defect in diamond that is an exquisite magnetometer and thermometer but arrives wrapped in a lump of diamond that must be introduced into the cell. That is the delivery problem: the particle settles where the cell's machinery leaves it, and steering one to a chosen protein on a chosen membrane is difficult work in its own right. Fluorescent proteins solved the equivalent labeling problem for microscopy thirty years ago without hardware, because they are genetically encodable. Work at Chicago showed that a fluorescent protein can also be operated as an optically addressable spin qubit, roughly ten times smaller than a diamond sensor.
What the record actually shows
The underlying result, published in Nature on August 20, 2025, realized a spin qubit in enhanced yellow fluorescent protein with up to twenty percent spin contrast on near-infrared triggered readout and a sixteen microsecond coherence time under standard decoupling, characterized near eighty kelvin. Three demonstration temperatures have to be kept apart: the full qubit characterization at liquid-nitrogen temperature, coherent control inside human embryonic kidney cells at one hundred and seventy-five kelvin, and optically detected magnetic resonance in living bacteria at room temperature with contrast up to eight percent. No coherent control was shown at human physiological temperature. The authors name photobleaching as the principal limitation and state that sensitivity still falls short of bulk-diamond nitrogen-vacancy sensors, and targeted fusion-protein sensing was not investigated in this study. This Monitor places the work at TRL 3 of 9: real physics, demonstrated in cells, with no clinical measurement and no animal or human study behind it yet.
Atrial Fibrillation Is Where Seoul Will Look for Quantum Advantage
A grant to find out whether quantum computing helps
On August 25, 2026 a Korean consortium was given two and a half years and 2.5 billion won to find out whether a quantum computer can compute cardiovascular blood flow on a schedule a clinic could live with. Seoul St. Mary's Hospital of the Catholic University of Korea, the University of Seoul and the medical software company Flownics were selected for a new 2026 challenge program run by Korea's Ministry of Science and ICT with the National Research Foundation. What the grant buys is a measurement rather than a product: the team has been funded to establish the conditions for quantum gain on one clinical calculation and to report those conditions as numbers, including how many circuits and how many measurements the answer cost.
What a hospital can already see, and what it cannot
A cardiologist reading a CT scan of a narrowed artery can measure the narrowing and cannot measure the flow. Velocity, pressure and wall shear stress are quantities that inform the risk of a clot forming or a muscle being starved, and none of them is in the picture. Computational fluid dynamics recovers them from the anatomy, and cardiology has begun buying it: pressure ratios computed from coronary CT are an established adjunct in stable chest pain assessment and have cleared a national payer's technology assessment in England. The trouble is what happens when a clinician asks for more. A finer mesh, honest nonlinear terms and patient-specific boundary conditions each multiply the arithmetic, and past a certain point the answer arrives too late to be part of a decision.
Atrial fibrillation first, adjudicated by imaging
The first target is atrial fibrillation, the most common sustained arrhythmia, present in roughly two to three percent of the population. In a fibrillating heart the left atrium stops emptying cleanly, blood stagnates in its appendage, and stagnation is where thrombus begins. Whatever the solver computes will be checked against real patients imaged with 4D Flow MRI, which records the speed and direction of the blood itself alongside the geometry of the vessels carrying it. The plan starts on classical hardware with a three-dimensional deep learning model that segments the heart, the left atrium and the aorta from CT, and a quantum hemodynamic model is built on top of that, stacking a variational algorithm, a Krylov subspace method, classical shadow measurement and non-Markovian error mitigation.
Ninety-five percent is a parity target
The headline figure deserves a careful reading. The stated aim is for quantum-based computational fluid dynamics to reach at least ninety-five percent of the precision of the classical method, which is a target to match the incumbent rather than to beat it. Any advantage the project finds will have to appear somewhere other than accuracy: in time to answer, in cost, or in problem sizes the classical solver cannot reach inside a clinical window. Stating it that way is unusually disciplined. The project fixes the accuracy at parity, names the baseline, names the disease, names the imaging modality that will adjudicate, and puts the burden of proof on resources. A hospital procurement officer has something to hold the team to in 2028, and a negative result in that year will be as informative as a positive one.
A Tenth of a Cent per Guess, and No Qubits in the Loop
A tenth of a cent per ranked pair
On August 19, 2026, SandboxAQ made a virtual screening model called AQPotency generally available. The company's release says it scores how strongly a candidate molecule is likely to act on a disease target, ranks molecule and target pairs in seconds, runs on ordinary computing hardware, and costs as little as one dollar per thousand comparisons. At the advertised minimum, a million pairwise rankings come to about a thousand dollars. Screening at that price stops being a budgeted event a team plans around and becomes something a chemist can run while thinking.
Screening without a solved protein structure
The claim that will interest a hospital pharmacologist sits one line further down. AQPotency is described as working without a solved protein structure, which makes it structure-free potency prediction: the model does not need a crystallographic or cryo-electron map of the target before it will score anything. A great many disease targets have no such map, and programs aimed at them have historically stopped at that wall. Cheap ranking only helps if the ranking is right, and the release publishes no accuracy figures. What it offers instead is eight customer programs with what the company calls experimentally validated impact, plus named academic collaborations. No independent evaluation, no prospective blinded benchmark and no head to head against an established free-energy method appears in the launch material.
The Parkinson's campaign has its own preprint
The launch quotes Gary Miller of Columbia University's Mailman School of Public Health on selective binders for SV2C, a synaptic vesicle protein implicated in Parkinson's disease. That campaign was posted to bioRxiv the same day, with a SandboxAQ corresponding author and Miller as final author. Its methods matter: because no full-length SV2C structure existed, the team built a homology model from SV2A cryo-electron microscopy templates, ran molecular dynamics, and applied a convolutional neural network scoring function inside a funnel that narrowed 5.96 million commercial compounds to 3.19 million before docking. Of 94 prioritized candidates, 71 were profiled and 22 were active. It is a genuine result on a target with no selective probes, and it is neither an AQPotency run nor a structure-free one.
The pillar field reads not applicable
Nothing in this announcement runs on a quantum computer. The most operationally ready development in today's quantum medicine pool comes from a company the quantum trade press covers closely, and the tool is classical software on conventional machines. One day later, a separate group posted a preprint on loading a molecule's wavefunction onto qubits at all, which is the step before any quantum chemistry happens. Both belong in the pool, and they sit at opposite ends of the readiness ladder.